Phase-II study of pomegranate juice for men with prostate cancer and increasing PSA

Current Urology Reports

Volumn 7, Issue 1, 2006, Pages 7-

  Pantuck, Allan J ^b   Zomorodian, Nazy ^b   Belldegrun, Arie S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CATECHIN; DAIDZEIN; ENTERODIOL; GENISTEIN; ISOFLAVONE DERIVATIVE; LIMONENE; PERILLYL ALCOHOL; PLANT EXTRACT; POMEGRANATE JUICE; PROSTATE SPECIFIC ANTIGEN; RESVERATROL; SULFORAPHANE; UNCLASSIFIED DRUG;

ARTICLE; BLOOD SAMPLING; CANCER RISK; CANCER SURGERY; CELL DIFFERENTIATION; CLINICAL TRIAL; DRUG EFFICACY; FOLLOW UP; GLEASON SCORE; HUMAN; POMEGRANATE; PROSTATE CANCER; URINALYSIS; APOPTOSIS; BLOOD; CHEMISTRY; DRUG EFFECT; MALE; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PROSTATE TUMOR;

ADMINISTRATION, ORAL; APOPTOSIS; CLINICAL TRIALS, PHASE II; HUMANS; MALE; PLANT EXTRACTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PUNICACEAE;

EID: 33744471415     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-006-0047-4     Document Type: Article

References (2)

1. Malik A, Afaq F, Sarfaraz S, et al.: Pomegranate fruit juice for chemoprevention and chemotherapy of prostate cancer. Proc Natl Acad Sci U S A 2005, 102:14813-14818.
2. D'Amico AV, Moul JW, Carroll PR, et al.: Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 2003, 95:1376-1383.